Results 181 to 190 of about 10,900 (261)

Challenges in the prophylaxis of severe respiratory syncytial virus infections. [PDF]

J Pediatr (Rio J)
Feitosa DC, Vieira SE.
europepmc   +1 more source

Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants. [PDF]

Clin Drug Investig
Bini C, Marcellusi A, Cazzato D, Muzii B, Soudani S, Bozzola E, Midulla F, Baraldi E, Bonanni P, Boccalini S, Orfeo L.   +10 more
europepmc   +1 more source

New Drugs: Palivizumab

Australian Prescriber, 1999
openaire   +1 more source

Direct Out-of-Pocket Costs of Nirsevimab <i>vs.</i> Palivizumab during the First Respiratory Syncytial Virus Season: A Comparative Analysis. [PDF]

Infect Chemother
Yun KW, Kang D.
europepmc   +1 more source

Impact of nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective. [PDF]

Front Pediatr
Tonetto S, Cason C, Fasiolo E, Dal Cin M, Cozzi G, Giangreco M, Zappetti C, Nider S, Amaddeo A, Comar M, Travan L.   +10 more
europepmc   +1 more source

Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study. [PDF]

BMJ Public Health
Gil-Prieto R, Pérez-Martín J, Díaz Aguiló A, Soudani S, Platero-Alonso L, López-Belmonte JL, de la Cuadra-Grande A, Casado MÁ, Álvarez Aldean J.   +8 more
europepmc   +1 more source

Addressing immunization gaps in children with congenital heart disease - a narrative review. [PDF]

Med Pharm Rep
Jecan-Toader D, Filip C, Căinap SS.
europepmc   +1 more source

The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy. [PDF]

Front Public Health
Lastrucci V, Pacifici M, Alderotti G, Puglia M, Berti E, Barbati F, Lodi L, Boscia S, Nieddu F, Indolfi G, Peroni D, Martini M, Azzari C, Voller F, Moriondo M, Ricci S.   +15 more
europepmc   +1 more source

Respiratory syncytial virus - from discovery to vaccines. [PDF]

J Med Microbiol
López EL, Ferolla FM, Acosta PL.
europepmc   +1 more source

Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis. [PDF]

Front Public Health
Soudani S, Bertizzolo L, Ghemmouri M, Chappell M, McCool R, Reddish K, Miller P, Barker E, Fewster H.   +8 more
europepmc   +1 more source